Who we are?

We are committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.

Our Pipeline

We focus on the discovery and development of innovative medicines to address significant unmet medical needs of diseases that are specially prevalence in Chinese population.

Dedicated and Deliver

We have built a fully integrated biopharmaceutical platform that allows us to oversee all aspects of the drug development cycle. By having all functions in-house, we are able to improve operational efficiency and control quality every step of the way.

Company News
26/05/2022

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China

11/04/2022

InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022

30/03/2022

InnoCare Announces Dosing of First Patient in Clinical Trial of RTK Inhibitor ICP-033 in China